1. BRIC Health Systems and Big Pharma: Strategic Policy Issues
Guilhem Fabre and Victor Rodwin
Université Paul Valéry Montpelier 3,
Wagner School of Public Service
New York University
June 5, 2017

2. Table 1. Age standardized mortality rates by cause (per 100 000 population) in BRIC nations
Communicable Disease (2012)
Non-communicable disease (2012)
Injury (2012)
Life expectancy at birth (2013)
Brazil 93
514 80 75
China 41
576 50
India
253
682
116 66
Russian Federation 74
790
103 69
France 21
313 35 82
Source: World Health Statistics 2015

3. Table 2. Burden of disease due to HIV/AIDS in the BRICS countries
Number of people (all ages) living with HIV (2015) [range]
Prevalence of HIV in adults (%) (2015) [range]
Number of deaths due to HIV/AIDS (2015)
Brazil
[ – ]
0.6 [0.4 – 0.8]
[ – ]
China
(Avert, 2014)
0.037% (avert, 2014)
deaths (avert, 2014)
India
[ – ]
0.3% (avert, 2015)
[ – ]
Russian Federation
[ ] (Avert, 2016)
0.8 – 1 (Avert, 2016)
(avert, 2014)
Sources: Avert.org, WHO Global Health Observatory Data Repository

4. Table 3. Burden of disease due to Tuberculosis in the BRICS countries
Number of deaths due to TB (excl. HIV) (2015)
Number of incident tuberculosis cases (2015)
Brazil
5 500 [ ]
[ – ]
China
[ – ]
[ – ]
India
[ – ]
[ – ]
Russian Federation
[ – ]
[ – ]

5. Cancer Mortality Estimates: BRIC Nations, France and US, 2012
Mortality (per people)
Brazil
103.72
Russia
122.55
India
64.49
China
122.19
France
107.93
United States
105.78
Source: Cancer Research UK – Worldwide Cancer Mortality Statistics

6. Table 4. Probability of dying between ages of 30 and 70 from cardiovascular disease, cancer, diabetes, or chronic respiratory (%) in 2015 and 2010 (both sexes)
2015
2010
Brazil 17 19
Russia 29 33
India 23 24
China 18
France 11 12
United States 14
Sources: WHO Global Health Observatory Data Repository

7. Table 5: Health Expenditures in BRIC Nations

8. IMS HEALTH. PHARMERGING MARKETS - PICKING A PATHWAY TO SUCCESS

9. Table 6. Pharmerging and Mature Markets
IMS HEALTH. PHARMERGING MARKETS - PICKING A PATHWAY TO SUCCESS

11. Table 7. Pharmerging Markets, 2008-2017
IMS HEALTH. PHARMERGING MARKETS - PICKING A PATHWAY TO SUCCESS

12. Table 8. China Leads the way

13. Watt, N. F. , Gomez, E. J. , & McKee, M. (2013)
Watt, N. F., Gomez, E. J., & McKee, M. (2013). Global health in foreign policy—and foreign policy in health? Evidence from the BRICS. Health Policy and Planning, N/A, /heapol/czt063

14. Table 9. BRIC Pharmaceutical Market
Brazil
Russia
India
China
Pharmaceutical Sales (in $ US Billion) (1)
18.38
15.4
17.45
116
Per Capita (in $ US) 88
107 13
8.3
Pharmaceutical Sales as % of Health Care Expenditures (2009) (2)
25%
20%
41%
42.5% (3)
% Expenditure on Patented Drugs 47 21
9.3 22
Pharmaceutical net Imports in $ US Billion (2016)(4)
2.4
6.5
11.3
Percent of Total Sales
13%
42% 0%
10%
(1) Forecast for 2016
(2) From Watt, Gomez, McKee, Global Health in Foreign Policy - and Foreign Policy in Health
th,Health Policy and Planning
nning (29),2014
(3) The figure for > is 17%
(4)Investorpedia, Daniel Workman, Drugs and Medicines Exports by Country
2017,5/15
Source: US Department of Commerce. International Trade Administration.
2016 Top Markets Report - Pharmaceuticals

15. Brazil
EMI, Brazilian Pharmaceutical sector, Dec. 2013

16. Structure of Russian Pharmaceutical Market
Deloitte, Development Trends and Practical Aspects of the Russian Pharmaceutical Industry, 2015

20. Chitour, Hind-Louiza, Big Pharma in China – the Driving Forces behind Their Success –A qualitative Analysis. Chinese Studies (2)4, 2013.

21. China
Hsaio W., Li M., Zhang S. Universal Health Coverage: The Case of China Working Paper, UNRISD